Your shopping cart is currently empty

BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1]. |
| In vitro | BTB01303 inhibits breast cancer cells from releasing high levels of glutamate, alleviating bone pain caused by glutamate-induced disruption of normal bone turnover [1]. |
| Molecular Weight | 324.16 |
| Formula | C15H11Cl2NO3 |
| Cas No. | 652129-89-0 |
| Smiles | N(=CC1=C(O)C(Cl)=CC(Cl)=C1)C=2C=C3C(=CC2)OCOC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.